Discontinued — last reported Q2 '23
MasTec Acquisitions increased by 473.1% to $266.85M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 5540.5%, from $4.73M to $266.85M. Over 4 years (FY 2021 to FY 2025), Acquisitions shows a downward trend with a -51.1% CAGR.
High spending indicates an aggressive growth strategy, while low spending may indicate a focus on organic growth or debt reduction.
This represents the net cash outflow for the purchase of other businesses or strategic assets, adjusted for any cash acq...
Highly variable; pharmaceutical companies frequently use M&A to offset patent cliffs and expand therapeutic portfolios.
acquisitions| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $500.41M | $15.85M | $639.70M | $21.84M | $23.07M | $26.93M | $563.92M | $46.51M | $17.37M | $4.94M | $571.00K | $61.00K | $0.00 | $33.75M | $46.12M | $4.73M | $2.52M | $17.23M | $46.57M | $266.85M |
| QoQ Change | — | -96.8% | >999% | -96.6% | +5.6% | +16.8% | >999% | -91.8% | -62.6% | -71.6% | -88.4% | -89.3% | -100.0% | — | +36.7% | -89.7% | -46.8% | +585.2% | +170.2% | +473.1% |
| YoY Change | — | — | — | — | -95.4% | +69.9% | -11.8% | +112.9% | -24.7% | -81.7% | -99.9% | -99.9% | -100.0% | +583.6% | >999% | >999% | — | -48.9% | +1.0% | >999% |